415 related articles for article (PubMed ID: 15975342)
1. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.
Raivio P; Suojaranta-Ylinen R; Kuitunen AH
Ann Thorac Surg; 2005 Jul; 80(1):66-71. PubMed ID: 15975342
[TBL] [Abstract][Full Text] [Related]
2. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
[TBL] [Abstract][Full Text] [Related]
3. Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.
Filsoufi F; Castillo JG; Rahmanian PB; Scurlock C; Fischer G; Adams DH
Ann Thorac Surg; 2006 Nov; 82(5):1779-83. PubMed ID: 17062247
[TBL] [Abstract][Full Text] [Related]
4. Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy.
von Heymann C; Redlich U; Jain U; Kastrup M; Schroeder T; Sander M; Grosse J; Ziemer S; Koscielny J; Konertz WF; Wernecke KD; Spies C
Crit Care Med; 2005 Oct; 33(10):2241-6. PubMed ID: 16215377
[TBL] [Abstract][Full Text] [Related]
5. Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.
Tatoulis J; Theodore S; Meswani M; Wynne R; Hon-Yap C; Powar N
Interact Cardiovasc Thorac Surg; 2009 Sep; 9(3):459-62. PubMed ID: 19542087
[TBL] [Abstract][Full Text] [Related]
6. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
Pychyńska-Pokorska M; Moll JJ; Krajewski W; Jarosik P
Pediatr Crit Care Med; 2004 May; 5(3):246-50. PubMed ID: 15115562
[TBL] [Abstract][Full Text] [Related]
7. Off-label use of recombinant factor VIIA concentrates after cardiac surgery.
Despotis G; Avidan M; Lublin DM
Ann Thorac Surg; 2005 Jul; 80(1):3-5. PubMed ID: 15975330
[No Abstract] [Full Text] [Related]
8. Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.
Razon Y; Erez E; Vidne B; Birk E; Katz J; Tamari H; Dagan O
Paediatr Anaesth; 2005 Mar; 15(3):235-40. PubMed ID: 15725322
[TBL] [Abstract][Full Text] [Related]
9. [The use of recombinant activated factor VII for blood loss after cardiovascular surgery].
Gong ZY; Gao CQ; Xiao CS; Li BJ; Ma XH; Zhang CM
Zhonghua Wai Ke Za Zhi; 2008 Oct; 46(19):1497-501. PubMed ID: 19094631
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
Chapman AJ; Blount AL; Davis AT; Hooker RL
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468
[TBL] [Abstract][Full Text] [Related]
11. Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery.
McCall P; Story DA; Karalapillai D
Can J Anaesth; 2006 Sep; 53(9):926-33. PubMed ID: 16960271
[TBL] [Abstract][Full Text] [Related]
12. Adequacy of hemostatic resuscitation improves therapeutic efficacy of recombinant activated factor VII and reduces reexploration rate for bleeding in postoperative cardiac surgery patients with refractory hemorrhage.
Feih JT; Juul JJ; G Rinka JR; Baumann Kreuziger LM; Pagel PS; Tawil JN
Ann Card Anaesth; 2019; 22(4):388-393. PubMed ID: 31621674
[TBL] [Abstract][Full Text] [Related]
13. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII inhibitor bypass activity and recombinant activated factor VII in cardiac surgery.
Rao VK; Lobato RL; Bartlett B; Klanjac M; Mora-Mangano CT; Soran PD; Oakes DA; Hill CC; van der Starre PJ
J Cardiothorac Vasc Anesth; 2014 Oct; 28(5):1221-6. PubMed ID: 25281040
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients.
Tobias JD; Simsic JM; Weinstein S; Schechter W; Kartha V; Michler R
J Intensive Care Med; 2004; 19(5):270-3. PubMed ID: 15358945
[TBL] [Abstract][Full Text] [Related]
16. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
17. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.
Guzzetta NA; Russell IA; Williams GD
Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310
[TBL] [Abstract][Full Text] [Related]
18. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
Murkin JM
Can J Anaesth; 2002 Dec; 49(10):S21-6. PubMed ID: 12546007
[TBL] [Abstract][Full Text] [Related]
19. Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass.
Guzzetta NA; Huch S; Fernandez JD; Tosone SR; Miller BE
Paediatr Anaesth; 2009 Apr; 19(4):364-70. PubMed ID: 19143947
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Outcomes Using Low-Dose and Early Administration of Recombinant Activated Factor VII in Cardiac Surgery.
Brase J; Finger B; He J; Wirtz K; Stun L; McMillen R; Flynn B
Ann Thorac Surg; 2016 Jul; 102(1):35-40. PubMed ID: 26874365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
